4875 Stock Overview
A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
MediciNova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$298.00 |
| 52 Week High | US$344.00 |
| 52 Week Low | US$155.00 |
| Beta | 0.77 |
| 11 Month Change | 17.32% |
| 3 Month Change | 24.69% |
| 1 Year Change | 11.19% |
| 33 Year Change | -17.22% |
| 5 Year Change | -64.78% |
| Change since IPO | -24.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4875 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 1.0% | 7.1% | -1.1% |
| 1Y | 11.2% | 20.3% | 10.7% |
Return vs Industry: 4875 underperformed the JP Biotechs industry which returned 20.3% over the past year.
Return vs Market: 4875 matched the JP Market which returned 10.7% over the past year.
Price Volatility
| 4875 volatility | |
|---|---|
| 4875 Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4875's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4875's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 13 | Yuichi Iwaki | www.medicinova.com |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company’s product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
MediciNova, Inc. Fundamentals Summary
| 4875 fundamental statistics | |
|---|---|
| Market cap | JP¥14.90b |
| Earnings (TTM) | -JP¥1.56b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs 4875 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4875 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.29m |
| Earnings | -US$10.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4875 perform over the long term?
See historical performance and comparison